Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity.

Saved in:
Bibliographic Details
Title: Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity.
Authors: Hanafin PO; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Mahadevan R; Titus Family Department of Clinical Pharmacy, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA., Rao GG; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Titus Family Department of Clinical Pharmacy, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA., Zavascki AP; Infectious Diseases Service, Hospital Moinhos de Vento, Porto Alegre, Brazil.; Department of Internal Medicine, Medical School, Universidade Federal, do Rio Grande do Sul, Porto Alegre, Brazil., Sandri AM; Infectious Disease Service, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.; Department of Internal Medicine, Medical School, Universidade Federal de Ciências da Saúde de Porto Alegre/Rio Grande do Sul, Porto Alegre, Brazil., Kwa A; Department of Pharmacy, Singapore General Hospital, Singapore City, Singapore.; Emerging Infectious Diseases, Duke-NUS Medical School, Singapore City, Singapore., Scheetz MH; Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois, USA., Kubin CJ; New York-Presbyterian Hospital, Columbia University Irving Medical Center, New York, New York, USA., Shah J; Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA., Cherng BPZ; Department of Infectious Diseases, Singapore General Hospital, Singapore City, Singapore., Yin MT; Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA., Wang J; Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia., Wang L; Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia., Calfee DP; Weill Cornell Medical College, New York, New York, USA., Bolon M; Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, Illinois, USA.; Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Purcell AW; Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia., Nation RL; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Pogue JM; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA., Li J; Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia., Kaye KS; Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2025 Oct; Vol. 118 (4), pp. 841-852. Date of Electronic Publication: 2025 Jun 16.
Publication Type: Journal Article; Observational Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-6535
DOI:10.1002/cpt.3729